サインイン 無料でサインアップします。

Last updated: 11 June 2024 at 4:15pm EST

Gary Bridger Net Worth



Gary Bridger XFOR stock SEC Form 4 insiders trading

Gary has made over 1 trades of the X4 Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 250,000 units of XFOR stock worth 2,500,000$ on 13 May 2014.

The largest trade he's ever made was buying 250,000 units of X4 Pharmaceuticals stock on 13 May 2014 worth over 2,500,000$. On average, Gary trades about 13,889 units every 0 days since 2014. As of 13 May 2014 he still owns at least 3,469,528 units of X4 Pharmaceuticals stock.

You can see the complete history of Gary Bridger stock trades at the bottom of the page.





Gary Bridger biography

Dr. Gary J. Bridger Ph.D. serves as Independent Director of the Company. Dr. Bridger served as a member of the X4 board of directors since October 2018. From February 2015 to December 2017, Dr. Bridger served as a consultant to Xenon Pharmaceuticals Inc., a biopharmaceutical company, where he previously served as the Executive Vice President of Research and Development from January 2013 to February 2015. From October 2013 to October 2015, Dr. Bridger served as a Managing Director at Five Corners Capital Inc. From June 2010 to June 2012, Dr. Bridger served as a venture partner at Venture West Capital Management, a venture capital firm. From November 2006 to December 2007, Dr. Bridger served as Senior Vice President of Research and Development of Genzyme Corporation, a biotechnology company, which was acquired by Sanofi, S.A. In June 1996, Dr. Bridger co-founded AnorMED Inc., a biopharmaceutical company, and was its Vice President of Research and Development and Chief Scientific Officer from 2000 until its acquisition by Genzyme in November 2006. Dr. Bridger has served on the board of directors of Aquinox Pharmaceuticals, Inc. since 2013. Dr. Bridger previously served on the board of directors of Alder BioPharmaceuticals, Inc., a biopharmaceutical company, from 2013 to 2016. Dr. Bridger serves on the scientific advisory board of Alectos Therapeutics Inc., a biopharmaceutical company. Dr. Bridger holds a Ph.D. in Organic Chemistry from the University of Manchester Institute of Science and Technology. Bridger’s experience as an executive officer or director of several public and private life sciences companies provides him with the qualifications and skills to serve on our board of directors.

What is the salary of Gary Bridger?

As the Independent Director of X4 Pharmaceuticals, the total compensation of Gary Bridger at X4 Pharmaceuticals is 132,433$. There are 6 executives at X4 Pharmaceuticals getting paid more, with Paula Ragan having the highest compensation of 2,497,790$.



How old is Gary Bridger?

Gary Bridger is 57, he's been the Independent Director of X4 Pharmaceuticals since 2019. There are 6 older and 8 younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals, Inc. is Dr. Robert David Arbeit, 73, who is the Sr. VP of Clinical Devel. and Translational Research.

What's Gary Bridger's mailing address?

Gary's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134.

Insiders trading at X4 Pharmaceuticals

Over the last 6 years, insiders at X4 Pharmaceuticals have traded over 2,179,690$ worth of X4 Pharmaceuticals stock and bought 25,000 units worth 30,000$ . The most active insiders traders include Paula Ragan、Adam S. Mostafa、Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of 12,232$. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth 1,744$.



What does X4 Pharmaceuticals do?

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.



What does X4 Pharmaceuticals's logo look like?

X4 Pharmaceuticals, Inc. logo

X4 Pharmaceuticals executives and stock owners

X4 Pharmaceuticals executives and other stock owners filed with the SEC include: